These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30685554)

  • 1. Spectrophotometric assessment of the brand new antiviral combination: Sofosbuvir and velpatasvir in their pure forms and pharmaceutical formulation.
    Rezk MR; Monir HH; Marzouk HM
    Spectrochim Acta A Mol Biomol Spectrosc; 2019 Apr; 213():159-166. PubMed ID: 30685554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous determination of the brand new two-drug combination for the treatment of hepatitis C: Sofosbuvir/ledipasvir using smart spectrophotometric methods manipulating ratio spectra.
    Eissa MS
    Spectrochim Acta A Mol Biomol Spectrosc; 2017 Aug; 183():362-370. PubMed ID: 28460317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Earth-friendly spectrophotometric methods for simultaneous determination of ledipasvir and sofosbuvir: Application to average content and uniformity of dosage unit testing.
    El-Shorbagy HI; Elsebaei F; Hammad SF; Elbrashy AM
    Spectrochim Acta A Mol Biomol Spectrosc; 2018 Dec; 205():398-409. PubMed ID: 30044997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of a sensitive and robust strategy for micellar electrokinetic chromatographic analysis of sofosbuvir in combination with its co-formulated hepatitis C antiviral drugs.
    Rageh AH; Abdel-Aal FAM; Pyell U
    J Chromatogr A; 2020 Apr; 1616():460795. PubMed ID: 31918849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of six sequential spectrophotometric methods for quantification and separation of ribavirin, sofosbuvir and daclatasvir: An application on Laboratory prepared mixture, pharmaceutical preparations, spiked human urine, spiked human plasma, and dissolution test.
    Hassan WS; Elmasry MS; Elsayed HM; Zidan DW
    Spectrochim Acta A Mol Biomol Spectrosc; 2018 Sep; 202():159-173. PubMed ID: 29783148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient HPTLC-dual wavelength spectrodensitometric method for simultaneous determination of sofosbuvir and daclatasvir: Biological and pharmaceutical analysis.
    Abo-Zeid MN; El-Gizawy SM; Atia NN; El-Shaboury SR
    J Pharm Biomed Anal; 2018 Jul; 156():358-365. PubMed ID: 29753282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a stability-Indicating RP-HPLC method for simultaneous estimation of sofosbuvir and velpatasvir in fixed dose combination tablets and plasma.
    Mehmood Y; Khan IU; Shahzad Y; Khalid SH; Irfan M; Asghar S; Yousaf AM; Hussain T; Khalid I
    Pak J Pharm Sci; 2019 Jul; 32(4(Supplementary)):1835-1842. PubMed ID: 31680080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.
    Younossi ZM; Stepanova M; Feld J; Zeuzem S; Jacobson I; Agarwal K; Hezode C; Nader F; Henry L; Hunt S
    J Hepatol; 2016 Jul; 65(1):33-39. PubMed ID: 26956698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validated spectrophotometric and chromatographic methods for analysis of the recently approved hepatitis C antiviral combination ledipasvir and sofosbuvir.
    Baker MM; El-Kafrawy DS; Mahrous MS; Belal TS
    Ann Pharm Fr; 2018 Jan; 76(1):16-31. PubMed ID: 28842163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new innovative spectrophotometric method for the simultaneous determination of sofosbuvir and ledipasvir.
    Mansour FR
    Spectrochim Acta A Mol Biomol Spectrosc; 2018 Jan; 188():626-632. PubMed ID: 28783604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of anti-Hepatitis C virus, sofosbuvir and daclatasvir, in pure form, human plasma and human urine using micellar monolithic HPLC-UV method and application to pharmacokinetic study.
    Zidan DW; Hassan WS; Elmasry MS; Shalaby AA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jun; 1086():73-81. PubMed ID: 29660665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel determination of sofosbuvir and velpatasvir in human plasma by UPLC-MS/MS method: Application to a bioequivalence study.
    Rezk MR; Basalious EB; Badr KA
    Biomed Chromatogr; 2018 Nov; 32(11):e4347. PubMed ID: 30047564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
    Younossi ZM; Stepanova M; Sulkowski M; Foster GR; Reau N; Mangia A; Patel K; Bräu N; Roberts SK; Afdhal N; Nader F; Henry L; Hunt S
    Clin Infect Dis; 2016 Oct; 63(8):1042-1048. PubMed ID: 27444413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study on fluorescence properties of HCV antiviral (velpatasvir) and its fluorimetric determination in presence of sofosbuvir; application to stability study and human plasma.
    Omar MA; Abdel-Lateef MA; Ali R; Derayea SM
    Luminescence; 2018 Nov; 33(7):1249-1256. PubMed ID: 30144265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved spectral resolution for the rapid simultaneous spectrophotometric determination of sofosbuvir and daclatasvir as anti hepatitis C virus drugs in pharmaceutical formulation and biological fluid using continuous wavelet and derivative transform.
    Keyvan K; Sohrabi MR; Motiee F
    Spectrochim Acta A Mol Biomol Spectrosc; 2021 Apr; 251():119429. PubMed ID: 33477087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study.
    Younossi ZM; Stepanova M; Sulkowski M; Wyles D; Kottilil S; Hunt S
    Liver Int; 2017 Dec; 37(12):1796-1804. PubMed ID: 28470938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of different mathematical models for simultaneous UV spectrophotometric quantitative analysis of velpatasvir and sofosbuvir.
    Abdelazim AH; Ramzy S; Abdelzaher AM; Shahin M
    Spectrochim Acta A Mol Biomol Spectrosc; 2022 Feb; 267(Pt 1):120536. PubMed ID: 34739999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three Smart and Original Spectrophotometric Data Processing Ratio Techniques for Resolving the Partial Overlapped Spectra of the Binary Antiviral Mixture Daclatasvir/Sofosbuvir: Application to Combined Dosage Form Darvoni® Tablets.
    Fayed AS; Hegazy MA; Kamel EB; Eissa MS
    J AOAC Int; 2022 Mar; 105(2):612-622. PubMed ID: 34623450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between core-shell and totally porous particle stationary phases for fast and green LC determination of five hepatitis-C antiviral drugs.
    Ibrahim AE; Hashem H; Elhenawee M; Saleh H
    J Sep Sci; 2018 Apr; 41(8):1734-1742. PubMed ID: 29297968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.
    Brieva T; Rivero A; Rivero-Juarez A
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):483-490. PubMed ID: 28165830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.